From Research at med.fsu.edu Thu Apr 4 08:52:51 2019 From: Research at med.fsu.edu (Med Research) Date: Thu, 4 Apr 2019 12:52:51 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE0190433952@FSUCOM128.med.ad.fsu.edu> March of Dimes: Child and Mental Health Research The March of Dimes is accepting applications through its 2019 Research Program for research on pregnancy-related disorders; the prevention and treatment of diseases in either mom, dad, or baby that lead to premature birth; genetic and environmentally-induced birth defects; opioid exposure and dependency; and health disparities within all these areas. Applicants are invited to submit LOIs in one of the following categories: * Innovative Challenge Grants -- Six-month grants of $50,000 will be awarded to proposals with clear-cut deliverables defined within the application. If the deliverables are achieved, there's a possibility of a second award in the amount of $100,000 to $500,000 over twelve months. * Novel Discovery Grants -- Proposals anywhere on the translational spectrum will be considered, including translation to humans, translation to patients, translation to practice, and translation to population health. Grants of $50,000 to $100,000 will be awarded for the first twelve months, with the option of an additional twelve months of support if significant progress is made. * Clinical and Social Science Challenge Grants -- MoD seeks research that explores health equity in order to reduce disparities; opioid dependency in mom, dad, and baby to mitigate the rise in Neonatal Abstinence Syndrome; and premature birth and maternal/infant mortality. Sic-month grants of $50,000 to $100,000 will be awarded to proposals with clear-cut deliverables defined within the application. If the deliverables are achieved, there's a possibility of a second award in the amount of $100,000 to $500,000 over twelve months. Letters of intent are due April 19, 2019. Med-RA deadline to receive draft documents: April 5. Prostate Cancer Foundation: Challenge Awards Through the program, awards of up to $1 million over two years will be made to teams of at least three investigators conducting large-scale research projects focused on metastatic, lethal prostate cancer. Teams must be based at a nonprofit academic research center, include one young investigator (as defined by the foundation), and be comprised of investigators at either a single institution or at several institutions. The foundation seeks research proposals dedicated to the following priority areas: immunotherapy for the treatment of metastatic, lethal prostate cancer; targeted radionuclide therapy for advanced prostate cancer; new systemic precision treatments for metastatic, lethal prostate cancer (including those targeting the currently "undruggable"); first-in-field research on new targets for systemic treatment of metastatic, lethal prostate cancer; mechanisms of resistance to current and investigational drugs targeting the androgen receptor and androgen axis, immune system, chemotherapy, and other targeted agents; correlative research around either clinical trials of novel agents or strategies or standard of care; the development or validation of biomarkers that can guide therapy in patients or further understanding of the mechanisms by which therapies work; tumor microenvironment signaling related to cancer progression (including the immune component); and new data science technologies for analysis of genomic information to advance precision medicine. Currently unfunded high-risk projects are encouraged. Young investigator team members may hold the title of postdoctoral fellow, instructor, research associate, or assistant professor (or equivalent), and should be within six years of the completion of a professional degree (MD, DO, PhD, MD-PhD, DSc, ScD, DDM, DDS, DMD, MBBS, or equivalent) or subsequent mentored academic or clinical training program. In addition, s/he must not receive more than $200,000 in direct research funding from all sources (including institutional funds) during the two-year term of the award. Due April 22, 2019. Med-RA deadline to receive draft documents: April 8. Michael J. Fox Foundation: Biology of Astrocytes in Parkinson's The Michael J. Fox Foundation will award one-year to 18-month grants for studies that explore the role of astrocytes in Parkinson's disease (PD) pathology and the potential for astrocyte-focused therapeutics. The goals of this funding program are to further understanding of astrocyte biology in Parkinson's and to rationalize the pursuit of astrocyte-specific targets and/or pathways for the treatment of the disease. Preference will be given to applications that focus on or include the following: * Role of astrocytes in initiating and/or propagating Parkinson's disease pathology, including alpha-synuclein spread, dopaminergic neuron death, inflammation and senescence * Consequences of dysfunction and/or mutations of common PD targets, including alpha-synuclein, LRRK2, GBA, PRKN and PINK1 * Manipulation of astrocyte activity and/or astrocyte-specific pathways to assess the potential of targeted astrocyte therapies on disease biology and/or symptoms * Parkinson's disease models with high construct validity to human PD, including patient-derived material (such as iPSCs or cerebral organoids) and/or well characterized animal models and primary cells; Examination of human brain samples to answer specific hypotheses is also acceptable * Targets, pathways and mechanisms proposed for investigation should have reasonable links to PD. Pre-proposals due April 19, 2019. Med-RA deadline to receive draft documents: April 5. Michael J. Fox Foundation: Assay Development and Validation for Quantifying Oligomeric Alpha-Synuclein The Michael J. Fox Foundation will award one-year grants for research to advance the development, optimization and validation of assays to quantify oligomeric alpha-synuclein in human body fluids. These biofluids may include blood, cerebrospinal fluid, saliva and tears. Prior research suggests that alpha-synuclein quantification in accessible body fluids may serve as a biomarker of disease diagnosis, target engagement, pharmacodynamic response and/or patient stratification. * Immuno-assays should have a renewable source of the antibodies used. Optimization and/or adaptation of existent assays to different biological matrices will also be considered. * Projects should propose to develop or optimize assays with superior performance in quantifying oligomeric alpha-synuclein and, at the end of the grant, should be able to present several performance parameters for further validation such as robustness, precision, trueness, uncertainty, limits of detection and quantification, dilutional linearity, parallelism, recovery, selectivity, and sample stability. Pre-proposals due April 19, 2019. Med-RA deadline to receive draft documents: April 5. Michael J. Fox Foundation: Imaging Biomarkers to Track Disease Progression and Therapeutic Efficacy The Michael J. Fox Foundation will award one- to three-year grants to develop imaging markers for use in disease-modifying clinical trials. Imaging is a powerful tool that can be used to visualize the structure and function of the brain in living subjects. While a variety of imaging techniques are available, including positron emission tomography (PET), single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI), none have been demonstrated to be a sensitive, specific and reliable biomarker test for the presence and progression of PD. Applications must focus on developing robust and precise imaging markers. * Priority targets for this program are alpha-synuclein and neuroinflammation, but applications may focus on other promising therapeutic targets. * Imaging modalities can include PET, SPECT and MRI. * Projects should aim to develop novel imaging biomarkers as opposed to prospectively collecting data using existing technologies. Prospective data collection is appropriate only if a novel imaging technique or tracer is being tested. Novel data analysis techniques may be proposed but should utilize existing data sets. * Examples of projects that are appropriate for this program include development of novel PET or SPECT tracers, early validation of new tracers, and development and validation of novel MRI techniques. Pre-proposals due April 19, 2019. Med-RA deadline to receive draft documents: April 5. Robert Wood Johnson Foundation: Pioneering Ideas Brief Proposal-Culture of Health The goal of the Pioneering Ideas Brief Proposal funding opportunity is to explore; to look into the future and put health first as we design for changes in how we live, learn, work and play; to wade into uncharted territory in order to better understand what new trends, opportunities and breakthrough ideas can enable everyone in America to live the healthiest life possible. While improving the status quo is vital to the health and well-being of millions of Americans now, the Pioneering Ideas Brief Proposal opportunity reaches beyond incremental changes to explore the ideas and trends that will influence the trajectory and future of health. Ultimately, we support work that will help us learn what a Culture of Health can look like-and how we can get there. Brief proposals are reviewed on a rolling basis, but the final deadline for submitting is October 15, 2019. Med-RA deadline to receive draft documents: Ten business days before submission. To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Apr 5 11:49:11 2019 From: Research at med.fsu.edu (Med Research) Date: Fri, 5 Apr 2019 15:49:11 +0000 Subject: Precision Health Funding Opportunity for FSU and UF investigators from the UF Clinical and Translational Science Institute In-Reply-To: <44823CD5-8CF2-4088-91F3-24BD7DACD37A@med.fsu.edu> References: <44823CD5-8CF2-4088-91F3-24BD7DACD37A@med.fsu.edu> Message-ID: <60E19361B71BE04F835C1FB3C18361BE0190433A11@FSUCOM128.med.ad.fsu.edu> [https://urldefense.proofpoint.com/v2/url?u=https-3A__gallery.mailchimp.com_125be93dc214597c36db124d4_images_c222166f-2D16a7-2D40a0-2D9be3-2D8d163ee2e731.png&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=eDo7hnmnroKPdGhvF_OW_Ch9xK1tH5b4CbkUrl2X32Q&s=lQ-w2qf8ZuuEZfEDv5tLk6gOGydZPJMGOqLGmYJDQCQ&e=] [https://urldefense.proofpoint.com/v2/url?u=https-3A__gallery.mailchimp.com_125be93dc214597c36db124d4_images_824e0859-2D0b1d-2D4bbe-2D95f9-2D286ad6558b96.jpg&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=eDo7hnmnroKPdGhvF_OW_Ch9xK1tH5b4CbkUrl2X32Q&s=EySqr3UNR4yMCCm2cuTZ0pfpkd_sIu0ZI05xXhw-jd8&e=] CTSI Precision Health Initiative Pilot Funding Opportunity Applications accepted through May 13, 2019 Attend an information session on April 10 (details below) As part of the Clinical and Translational Science Award collaboration between the University of Florida and Florida State University, we welcome proposals in response to this RFA that support the development of methods, interventions or integrative models with the potential to advance precision health. See below for details on an upcoming information session and resources that might be helpful to applicants. To view the full RFA, visit our website here or download the PDF here. Definitions Precision Medicine An ?approach for disease prevention and treatment that takes into account individual differences in lifestyle, environment, and biology.? - NIH All of Us Program: https://urldefense.proofpoint.com/v2/url?u=https-3A__allofus.nih.gov_about_about-2Dall-2Dus-2Dresearch-2Dprogram&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=eDo7hnmnroKPdGhvF_OW_Ch9xK1tH5b4CbkUrl2X32Q&s=jc5HisP86wjT1Syecd2xnZkLYuBWb0C5LUbH2QqWWpo&e= Precision Public Health "Improving the ability to prevent disease, promote health, and reduce health disparities in populations by: 1) applying emerging methods and technologies for measuring disease, pathogens, exposures, behaviors, and susceptibility in populations; 2) developing policies and targeted implementation programs to improve health.? - Precision Public Health and Precision Medicine: Two Peas in a Pod (https://urldefense.proofpoint.com/v2/url?u=https-3A__blogs.cdc.gov_genomics_2015_03_02_precision-2Dpublic&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=eDo7hnmnroKPdGhvF_OW_Ch9xK1tH5b4CbkUrl2X32Q&s=Exy-oCUIQzfMx1aLKmGS8nfNmWJZrVgtPdsfMpETD7M&e=/) Funding and awards The CTSI will make a total of up to $200,000 available through this RFA depending on the quality of submissions and budget availability. Teams may apply for awards of up to $50,000 each. Eligibility * This Pilot RFA is open to investigators at UF and Florida State University. Applicants are strongly encouraged to include an investigator from each institution, and principal investigators (PIs) must meet the requirements for PI status as specified by their home institution. * Applicants must assemble project teams that include investigators from at least two colleges, and must include at least one trainee for a mentored research experience. Single-investigator proposals are not eligible. * Applicants can only submit one application for which they are the PI, but individuals can be listed as co-investigators on more than one proposal. * Recipients of previous CTSI Pilot Awards are eligible to apply for awards to support new research projects, as long as previous projects have been completed. * Animal studies are not allowed. Deadlines Applications can be submitted in response to this RFA on any date between April 3, 2019 and May 13, 2019 (by 5 p.m.) UF applicants should submit to Elizabeth Eddy, MPH, elizabetheddy at ufl.edu FSU applicants should submit to Terra Bradley, PhD, terra.bradley at med.fsu.edu. Successful applicants will have up to 12 months from date of NIH approval to complete their projects. Information Session Questions? Join an information session remotely to hear from CTSI Precision Health Initiative leaders. Wednesday, April 10, 2019 3:30 p.m. to 4:30 p.m. Log in Via Zoom https://urldefense.proofpoint.com/v2/url?u=https-3A__uflphi.zoom.us_j_210074245&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=eDo7hnmnroKPdGhvF_OW_Ch9xK1tH5b4CbkUrl2X32Q&s=zcS7JRNc5ZyAMQEwj-6QtTCxVpTKbKx2I05-JPcPq3w&e= Contact Please email questions to Terra Bradley, PhD, terra.bradley at med.fsu.edu or Elizabeth Eddy, MPH, elizabetheddy at ufl.edu. Applicants are encouraged to visit the CTSI website to learn about additional services available to facilitate research at UF. Are you a Florida State University researcher who's interested in precision health? Join our email list to hear about future pilots and collaboration opportunities. Subscribe for email updates here . Questions? Comments? CTSI Main Line: (352) 273-8700 Website: https://urldefense.proofpoint.com/v2/url?u=http-3A__www.ctsi.ufl.edu&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=eDo7hnmnroKPdGhvF_OW_Ch9xK1tH5b4CbkUrl2X32Q&s=D1qQExFBZsoe1bkp8sb0G_EBAith8XnTBtx0b-caU1M&e= Copyright ? 2016 UF Clinical and Translational Science Institute, All rights reserved. You are receiving this email because you are subscribed to the CTSI-Announce mailing list. Our mailing address is: UF CTSI University of Florida Health Science Center Gainesville, FL 32611-0001 Add us to your address book Want to change how you receive these emails? You can update your preferences or unsubscribe from this list The UF CTSI is supported in part by NIH Clinical and Translational Science Awards UL1TR001427, KL2TR001429 and TL1TR001428. This content is solely the responsibility of the UF CTSI and does not necessarily represent the official views of the NIH. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Apr 5 13:34:40 2019 From: Research at med.fsu.edu (Med Research) Date: Fri, 5 Apr 2019 17:34:40 +0000 Subject: OVPR Program for Partial Salary Funding of Full-Time Specialized Research Faculty Message-ID: <60E19361B71BE04F835C1FB3C18361BE0190433AC0@FSUCOM128.med.ad.fsu.edu> Applications for FY 19-20 funding are due by May 24. If you intend to apply for this funding, please notify Med-RA (research at med.fsu.edu) 10 days prior to submittal. ________________________________ [Research Logo] OVPR Program for Partial Salary Funding of Full-Time Specialized Research Faculty The Office of the Vice President for Research (OVPR) will provide funding to cover 5% of current salary plus applicable fringe benefit coverage for certain full-time specialized research faculty supported exclusively by Federal research contract or grant funds to recognize their participation in proposal development and writing. Applications for funding may be submitted by individuals who are PIs on grants or other key senior individuals who take time away from their funded research to actively engage in successful efforts to obtain additional extramural funding. Eligibility for this program will be reviewed and confirmed by the OVPR. For clarity, the OVPR will provide funding only for the research activities defined in this notice. Funding for other non-project related activities should be sought from departmental or other sources. In no case should individuals engage in activities outside of their funded research if those additional activities would occur while being supported by an unrelated research contract or grant. It is our intent that upon approval of an application, funding for the applicant could be made available for a period of up to 3 years contingent upon annual certification that the approved individuals are continually engaged in efforts to obtain extramural research funding. All awards approved under this program will be made at the discretion of the OVPR. The application form should be used for funding requests and should be submitted to the OVPR via Kerry Peluso (kpeluso at fsu.edu) for consideration at least five weeks prior to the beginning of the fiscal year in which funds are needed. The application form is available at https://www.research.fsu.edu/research-offices/sra/policies-procedures/pilot-program/. If you have any questions, please contact Kerry Peluso at kpeluso at fsu.edu or 850-644-8664. -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image001.jpg Type: image/jpeg Size: 4073 bytes Desc: image001.jpg URL: From Research at med.fsu.edu Wed Apr 10 15:53:46 2019 From: Research at med.fsu.edu (Med Research) Date: Wed, 10 Apr 2019 19:53:46 +0000 Subject: Weekly Funding Opportunities In-Reply-To: <678887EBDC79FB438BFD062B064C59A40136DD2A3B@FSUCOM128.med.ad.fsu.edu> References: <78AD6384-24CE-46B5-BC2A-7279104756AA@med.fsu.edu> <60E19361B71BE04F835C1FB3C18361BE0190433E80@FSUCOM128.med.ad.fsu.edu> <678887EBDC79FB438BFD062B064C59A40136DD2A3B@FSUCOM128.med.ad.fsu.edu> Message-ID: <60E19361B71BE04F835C1FB3C18361BE0190433EBE@FSUCOM128.med.ad.fsu.edu> Using Data Analytics to Support Primary Care and Community Interventions to Improve Chronic Disease Prevention and Management and Population Health (R18) The purpose of this FOA is to invite applications to promote health equity and improve the health of individuals and populations at risk for suboptimal health outcomes through the use of primary care and community interventions that address chronic conditions, including prevention and management of multiple chronic conditions. This is to be accomplished by developing data resources, applying health services research methodologies and presenting data analytics to primary care providers, health care delivery systems, public health departments, and/or community organizations to help them address social determinants of health (SDOH) and contribute to the delivery of whole person, 360-degree care that meets physical, behavioral, and oral health, as well as social services, needs. Due May 29, 2019. Med-RA deadline to receive draft documents: May 14. AHRQ Health Services Research Project: Partners Enabling Diagnostic Excellence (R01) The purpose of this funding opportunity announcement (FOA) is to fund investigative health services research projects that establish the incidence of diagnostic errors, enhance our understanding of the factors contributing to diagnostic errors, and the association between diagnostic safety and quality and outcomes such as patient harms, costs, expenditures, and utilization.As an HHS Operating Division, AHRQ is committed to addressing the HHS Secretary?s priorities and encourages applicants to address one or more of the Secretary?s priorities. Of those priorities, this funding opportunity announcement is likely to be most relevant to addressing the opioid crisis and patient safety aspects of value-based care. Due May 29, 2019. Med-RA deadline to receive draft documents: May 14. Overview The American Association for Cancer Research, in partnership with healthcare investment firm MPM Capital, is inviting Letters of Intent for its Oncology Charitable Foundation Transformative Cancer Research Grants program. A new funding initiative, the program is intended to stimulate high-risk, high-reward research by early- to mid-career investigators and promote and support creative, paradigm-shifting cancer research that might not be funded through conventional channels. It is expected that grants awarded through the program will catalyze significant scientific discoveries that advance understanding of cancer and have a potentially transformative impact on future clinical practice. Though the program, grants of up to $400,000 over two years will be awarded for any type of basic, translation, or clinical research. Letter of intent due May 10, 2019. Med-RA deadline to receive draft documents: April 29. Lalor Foundation: Advancing Research and Innovation in Reproductive Health The Anna Lalor Burdick (ALB) Program supports programs that offer sexual and reproductive health education to young women. It is interested in programs serving young women who are disadvantaged by poverty, discrimination, geographic isolation, lack of comprehensive sex education, hostile public policy, or other factors leading to inadequate sexual and reproductive health. The ALB Program is particularly interested in supporting new programs or initiatives, or innovations in successful programs. Programs at new or small organizations, including those with a grassroots base, that are capable of delivering excellent services will also be considered. The ALB Program awards a small number of grants in the range of $10,000 to $35,000, with an average grant size between $15,000 and $25,000. Grants are awarded for one year. Concept papers due May 1, 2019 and November 1, 2019. Med-RA deadline to receive draft documents for May deadline: April 22. Bristol-Myers Squibb/Pfizer Alliance Independent Medical Education/Global Medical Grant: Quality Improvement Initiatives for Undiagnosed Nonvalvular Atrial Fibrillation (NVAF) This program will support Quality Improvement (QI) initiatives that focus on decreasing the number of people with undiagnosed/ untreated NVAF (i.e., diagnosed but not anticoagulated as per guidelines) within healthcare teams, especially those with increased risk factors, such as age ?65 years, heart failure (left ventricular dysfunction), hypertension, diabetes, prior stroke or embolism, and vascular disease (peripheral vascular disease, prior MI, or aortic plaque). Of specific interest are QI initiatives that increase awareness of the burden and consequences of the undiagnosed/untreated NVAF (i.e., diagnosed but not anticoagulated as per guidelines) population and provide tools to improve identification of undiagnosed NVAF and help reduce risk of preventable stroke. Due May 7, 2019. Med-RA deadline to receive draft documents: April 23. Alzheimer?s Drug Discovery Foundation / Diagnostics Accelerator: Digital Biomarkers Through this RFP, ADDF seeks proposals for the development and validation of digital biomarkers for Alzheimer?s disease and related dementias. Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected, measured, and analyzed by means of digital devices such as portables, wearables, or ambient sensors. They can range from computerized or app-based versions of traditional neurocognitive tests to novel technology platforms that combine multiple complex data sources into a phenotypic signature. Proposals addressing a range of potential clinical uses are of interest, especially technologies for early assessment and those aiding in diagnosis and monitoring treatment response or rate of disease progression. Creative approaches that leverage new and existing software and hardware are encouraged. The use of the digital technology should be driven by 1) an unmet patient or scientific need for a better assessment; and/or 2) providing a more cost-effective, efficient, and less burdensome approach to diagnosis and monitoring in clinical practice and clinical trials. Symptom domains of interest include but are not limited to cognition (e.g., memory, processing speed, executive function, or geolocation); speech and language (e.g., written text or vocal features); activities of daily living (instrumental basic activities or higher-order activities); motor function (e.g., gait, body motion, or fine motor skills, including tapping, swiping, and tracing on touchscreens); sensory acuity (e.g., hearing, smell); affect (e.g., mood, facial expression); sleep patterns and characteristics; occulomotor (e.g., eye movement); pain assessment; and/or autonomic nervous function (e.g., heart rate, galvanic skin response). Three project stages will be supported through this RFP: Exploratory awards: Awards of awarded up to $250,000 (based on stage and scope of research) will support pilot studies that aim to test the utility of an existing digital technology for the first time in Alzheimer?s disease or a related dementia population. Projects should already have preliminary human data from another disease indication. Only proposals with evidence demonstrating that the technology or prototype can reliably capture, process, store, and transfer data from a clinical population will be considered. A limited number of awards will be considered in this category. Proof-of-principle awards: Awards of up to $500,000 (based on stage and scope of research) will support projects that demonstrate feasibility and/or verify that a certain approach has potential for use in Alzheimer?s disease or related dementias. Preliminary data from human subjects with the proposed indication is expected and must demonstrate that the technology or prototype is capable of the reliable capture, processing, storage, and transfer of valid data to test in the clinical population Validation awards: These awards will support projects that require testing at a larger scale as well as access to patients of varying demographic diversity to demonstrate clinical relevance. The technology must be verified and validated, and data quantifying the accuracy, precision, consistency, and uniformity of the technology must be provided. Applicants will be required to address scalability considerations, clinical integration plans, and anticipated regulatory considerations and commercialization. Data sharing policies and standards, intellectual property restrictions, and standard operating procedures should be well defined. Validation studies should prioritize comparisons using existing gold standard approaches to diagnose and monitor such as neuroimaging and/or CSF measurements, as well as clinical tests such as cognition, but this is dependent on the context of use. These studies will require a comprehensive experimental plan with larger sample size (e.g. 500-1000+ subjects based on power analyses). Award amounts will be based on the stage and scope of the research. Letter of Intent due June 7, 2019. Med-RA deadline to receive draft documents: May 23. Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators: (1) from diverse backgrounds, including from groups nationally underrepresented in biomedical and behavioral research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Human Genome Research Institute (NHGRI) and (2) who at the time of award under this FOA will have/have had less than $125,000 direct cost of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of diverse New Investigators. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Standard dates apply. Expires May 8, 2022. Med-RA deadline to receive draft documents for June deadline: June 3. Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed. All the proposed P20 programs must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees. Due June 19, 2019; October 18, 2019; June 19, 2020; and October 18, 2020. Med-RA deadline to receive draft documents for June deadline: June 5. Paralyzed Veterans of America Research Fellowships and Grants: Spinal Cord Injury and Disease From transplanting cells and regenerating damaged nerve fibers to designing adaptive canoe seats, the Paralyzed Veterans of America Research Foundation supports innovative research and fellowships that improve the lives of those with spinal cord injury and disease (SCI/D). The Research Foundation, a 501(c)(3) nonprofit, funds the following categories: * Basic Science - laboratory research in the basic sciences to find a cure for SCI/D * Clinical - clinical and functional studies of the medical, psychosocial and economic effects of SCI/D, and interventions to alleviate these effects * Design and Development - of assistive technology for people with SCI/D, which includes improving the identification, selection and utilization of these devices * Fellowships - for postdoctoral scientists, clinicians and engineers to encourage training and specialization in the field of spinal cord research Due July 1, 2019. Med-RA deadline to receive draft documents: June 17. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Thu Apr 18 14:41:07 2019 From: Research at med.fsu.edu (Med Research) Date: Thu, 18 Apr 2019 18:41:07 +0000 Subject: Funding opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE01904344D8@FSUCOM128.med.ad.fsu.edu> Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Abuse and Addiction Scientists (R25 ? Clinical Trials Not Allowed) The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: * Research Experiences * Courses for Skills Development This NIDA R25 Education Program will provide the resources needed to assist with the preparation of individuals from diverse backgrounds to successfully transition to the subsequent professional career stage. This FOA invites applications from established researchers with a record of NIH funding, who can demonstrate that they have successfully guided previous early career scientists to independent research careers and are able to direct an educational research capacity building program. This program intends to strengthen the pipeline of individuals in biomedical, behavioral, and clinical substance abuse and addiction research across various stages of the research pipeline to enhance the number of independently funded investigators from diverse backgrounds, including from underrepresented groups. NIDA also expects that efforts and resources from this program will also foster a greater understanding of the implications of substance abuse and addiction nationwide and contribute to the biomedical research workforce which will help to develop solutions to reduce the burden of substance abuse, addiction, and their health-related consequences across all populations. To that end, NIDA encourages research experiences to include, but not limited to: cellular and molecular neuroscience, neuroimaging, genetics, medication and treatment development, pain and analgesia, neuroimmune signaling, neuropathology in brain systems, cognitive processes, population neuroscience, delivery of HIV and substance abuse prevention and treatment services, medication development, epidemiology of substance abuse, and implementation science, including secondary data analysis. In addition, American Indians and Alaska Natives experience tremendous disparities in substance abuse and addiction, having the highest rates of abuse and addiction relative to other racial/ethnic groups, and experience high rates of negative consequences from substance abuse. Research addressing American Indian and Alaska Native substance abuse and addiction health related disparities is particularly encouraged. A milestone plan with timelines and metrics is required for all applications. The detailed milestone plan will be used to evaluate the application during peer review and in consideration of the awarded project for funding of non-competing award years. The milestone plan will be used to evaluate the research experiences and technical training of participants; formal mentoring plans and professional career development activities completed by participants; NIH application and manuscript submissions from participants; courses for skills development offered, participant participation, and feedback; and when appropriate, the successful graduation or transition of participants to the subsequent career stage. Applicants can focus on a single career stage or encompass multiple career stages (undergraduate students, predoctoral students, postdoctoral fellows, and/or early-stage investigators) within their approach, but must include research experiences, and courses for skills development to prepare participants to successfully transition to the subsequent professional career stage as components of the program. Due June 12, 2019; July 15, 2020; and July 15, 2021. Med-RA deadline to receive draft documents for 2019 date: May 29. One Mind Rising Star Research Awards: Accelerate Research on Major Neuropsychiatric Disorders This program seeks to fund research directed at understanding the fundamental characteristics and biological mechanisms of brain function and dysfunction, as well as the translation of basic science mechanisms into better diagnostics and treatments for neuropsychiatric disorders. Of particular interest is research dedicated to schizophrenia and/or depression. Studies that use exiting data and collaborations to accelerate discovery and knowledge also are encouraged. Examples of relevant research through this opportunity include but are not limited to studies focused on the biological mechanisms of neuropsychiatric and/or neurotraumatic disorder(s); the identification of pharmacological and non-pharmacological therapeutic targets; the development of new or refinement of existing models for studying neuropsychiatric and/or neurotraumatic disorders; the development of new or improvement of existing tools for studying brain health; the identification or advancement of biomarker development for neuropsychiatric disorder(s); the development of targeted therapies to prevent the onset or progression of neuropsychiatric disorders, mitigate their negative effects on brain function and behavior, and/or promote recovery; the characterization of similarities and differences in biological mechanisms between two or more neuropsychiatric disorders, and/or characterization of the effects of comorbid conditions on diagnosis, prognosis, and treatments; the external validation of promising biomarkers, diagnostic tools, and treatments; a comparison of the effects of treatments on whole or select patient populations; and the generation of new hypotheses from existing clinical data and their testing in relevant preclinical or computational models, or in small pilot clinical studies. Applicants whose proposals can be enhanced with optical methods to investigate links between neural circuit/ensemble dynamics and disease phenotypes are encouraged to apply for a supplemental technology grant from Inscopix. Proposals within this category might include but are not limited to signal analysis in health vs. disease, and/or how circuit/ensemble signatures change and evolve during disease progression and in therapeutic intervention paradigms; studies that use established or new rodent models of neuropsychiatric disorders to extract key characteristics of the pathophysiology in a cell type- and/or circuit-specific manner; and investigations into the causal role of disease circuit/ensemble dynamics identified with nVoke/nVista and potentially in conjunction with other methods such as pharmacology, chemogenetics, electrophysiology, and cell ablation. Up to five award recipients will receive $250,000 over three years. In addition, up to three supplemental technology grants will be awarded, with each including a state of the art nVoke miniature microscope system, full scientific support, and full technical support. Applicants may apply for the technology grant only as a supplement to a Rising Star Award proposal and cannot apply for the technology grant by itself. To be eligible, candidates should be within ten years of their initial independent appointment and have demonstrated productivity and innovation in a scientific field that can be applied to the study of neuropsychiatric disorders such as attention-deficit hyperactivity disorder (ADHD), anxiety, addiction, bipolar disorder, depression, post-traumatic stress, schizophrenia, traumatic brain injury, digital therapies, or other field relevant to brain health. Due May 15, 2019. Med-RA deadline to receive draft documents: May 1. Alex?s Lemonade Stand: ?A? Awards The foundation is currently accepting applications for its ?A? Award. Through the program, a grant of up to $800,000 over four years will be awarded to an independent early-career researcher seeking to establish a career in pediatric oncology research who has demonstrated a future commitment to pediatric cancer investigation and has institutional support for his/her career development. The ideal applicant should have original research that is not currently being funded, with the goal of advancing knowledge that will lead to new treatments and cures for children with cancer. Eligible applicants must have an MD, PhD, or dual MD PhD (DO, MBBS, or equivalent) and be within five years of their first faculty appointment as an assistant professor. Applicants may have research grants from other funding sources during the ?A? Award period, but there must be clear documentation of mechanisms to avoid scientific and budgetary overlap. Investigators cannot have a K99/R00 or an R01 that has been funded, or have been recommended for such funding (i.e., expect to be funded), at the time they apply. Due May 20, 2019. Med-RA deadline to receive draft documents: May 6. Accelerating Medicine Partnership in Parkinson?s disease (AMP PD) unbiased proteomics biofluid analysis (U01 Clinical Trials Not Allowed) The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from Accelerating Medicine Partnership in Parkinson's disease (AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression. Proteomics data generated through this initiative will be broadly shared with the research community through the AMP PD Knowledge Portal to enable additional analyses and data integration across the various datatypes available through AMP PD. A staged approach will be used to first identify and address pre-analytical variables and then incorporate that information into the optimal design for the analysis of 4500 CSF and plasma samples. Due May 29, 2019. Med-RA deadline to receive draft documents: May 14. Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R21 / R01 Clinical Trial Not Allowed) R21 R01 The purpose of these Funding Opportunity Announcements is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines. Due June 18, 2019; June 18, 2020; and June 18, 2021. Med-RA deadline to receive draft documents for 2019 date: June 4. Development of Sample Sparing Assays for Monitoring Immune Responses (U24 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to accelerate the development and validation of sample sparing assays that can be applied for studying the human immune system in health and disease. Development of new, cutting-edge sample sparing assays will lead to maximum use of the human-derived specimens by significant reduction of sample volumes/amounts required or by simultaneous multi-parameter assessments of immune function. Due July 30, 2019. Med-RA deadline to receive draft documents: July 16. Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders. Due October 21, 2019; October 19, 2020; and October 19, 2021. Med-RA deadline to receive draft documents for 2019 date: October 7. Informatics Methodology and Secondary Analyses for Immunology Data in ImmPort (UH2 Clinical Trial Not Allowed) The goals of this Funding Opportunity Announcement are to support the development of new or improved informatics tools and methods for the reuse of shared data in the immunology study repository, ImmPort, and to support secondary analyses of existing immunology datasets to address basic and clinical immunology questions. Due October 1, 2019; October 1, 2020; and October 1, 2021. Med-RA deadline to receive draft documents for 2019 date: September 17. Pragmatic clinical trial on efficacy of managing reduced iron stores on risk of clinically important events in older adults with heart failure and anemia (U01 Clinical Trial Required) This FOA invites applications for a pragmatic clinical trial to establish efficacy of managing reduced iron stores on risk of clinically important events in older adults with heart failure and anemia. Standard dates apply. Expires July 6, 2022. Med-RA deadline to receive draft documents for June 2019 date: May 22. Reducing the Duration of Untreated Psychosis in the United States (R34 / R01 Clinical Trial Required) R34 R01 Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, the R34 Funding Opportunity Announcement (FOA) seeks planning research project grant applications that (1) identify a baseline rate of DUP in community or institutional settings; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP. Alternatively, applicants who have already completed significant developmental or pilot work in this area are encouraged to apply to the companion R01 FOA. Standard dates apply. Expires May 8, 2022. Med-RA deadline to receive draft documents for June 2019 date: May 22. Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation. Standard dates apply. Expires May 8, 2022. Med-RA deadline to receive draft documents for June 2019 date: May 22. BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) encourages secondary analysis of the large amounts of existing data related to the BRAIN Initiative. The data do not need to be held in one of the funded BRAIN Initiative data archives, but the data must be held in a data archive that is readily accessible to the research community. Support will be provided for innovative analysis of relevant existing datasets using conventional or novel analytic methods, data science techniques, and machine learning approaches. Support may also be requested to prepare and submit existing data into any of the BRAIN Initiative data archives. Investigators should not underestimate the time and effort that may be necessary to curate or harmonize data. Analyzed data, models and analytical tools generated under this FOA are expected to be deposited into an appropriate data archive. Since the BRAIN Initiative data archives are mostly making the data available to the research community through cloud-based storage, depositing the analyzed data, models and tools are expected to enhance opportunities to create a data sandbox where investigators can easily compare the results of their analysis with those from other research groups. The goal of this FOA is to promote studies that will significantly advance new discoveries and accelerate the pace of research of the BRAIN Initiative through harnessing the big data and machine learning opportunities. Awardees are expected to enhance the value of existing data, improve the overall data integration and analysis capability, and strengthen the statistical power and rigor and reproducibility of BRAIN Initiative related data. Due September 6, 2019 and June 11, 2020. Med-RA deadline to receive draft documents for September 2019 date: August 22. NIH Director?s Pioneer Award Program (DP1 Clinical Trial Optional) The NIH Director?s Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative research towards the ultimate goal of enhancing human health. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator?s research program or elsewhere. The NIH Director?s Pioneer Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund. Due September 9, 2019. Med-RA deadline to receive draft documents: August 23. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Tue Apr 23 14:51:37 2019 From: Research at med.fsu.edu (Med Research) Date: Tue, 23 Apr 2019 18:51:37 +0000 Subject: This week's funding opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE0190434B20@FSUCOM128.med.ad.fsu.edu> Updated Congressionally Directed Medical Research Programs including the Spinal Cord Injury Research Program, the Parkinson?s Research Program, and the Prostate Cancer Research Program. Law Enforcement Mental Health and Wellness Act (LEMHWA) Program LEMHWA funds are used to improve the delivery of and access to mental health and wellness services for law enforcement through training and technical assistance, demonstration projects, and implementation of promising practices related to peer mentoring mental health and wellness programs that are national in scope and responsive to the solicitation topic requirements. The 2019 LEMHWA program will fund projects that develop knowledge, increase awareness of effective mental health and wellness strategies, increase the skills and abilities of law enforcement, and increase the number of law enforcement agencies and relevant stakeholders using peer mentoring programs. LEMHWA program will fund projects related to the following topic areas: * LEMHWA Peer Mentoring Training and Support * LEMHWA Recommendation Implementation * LEMHWA Peer Support Implementation Projects Proposals should be responsive to the topic selected, improve the delivery of and access to mental health and wellness services for law enforcement, and significantly advance peer mentoring mental health and wellness programs within law enforcement agencies across the country. Due May 28, 2019. Med-RA deadline to receive draft documents: May 13. Children's Cancer Research Fund: Emerging Scientist Award The Children?s Cancer Research Fund Emerging Scientist Award is designed to develop the independent research of highly qualified individuals still early in their careers. Research projects must have direct applicability and relevance to pediatric cancer. They may be in any discipline of basic, clinical, translational, or epidemiological research. An Emerging Scientist Award is $100,000 for a one-year period. Due May 30, 2019. Med-RA deadline to receive draft documents: May 15. American Cancer Society and Pfizer: Integrated Approach to Breast Health Equity The intent of this community grants project is to focus on reducing the widening gap in breast cancer mortality trends between black and white patients. Target audience: * Members of the health care team and administrators involved in the diagnosis and care of breast cancer patient * Patients * Community health workers * All groups dedicated to reducing breast cancer disparities Community Engaged Projects: Focusing on innovative, community-wide, clinical practice or health systems engaged projects. May request up to $350,000. Formative Projects: Focusing on assessment only. May request up to $50,000. Letter of intent due June 17. Med-RA deadline to receive draft documents: June 3. Epilepsy Foundation: My Brain Map Initiative This initiative seeks to better define personalized modeling of seizure propagation to transform care in epilepsy, with the end goal of creating a Google Map for the brain that highlights one?s unique brain traffic pattern over time. Through the program, grants of up to $200,000 will be awarded to pilot studies that propose new analytical approaches and/or tools to modeling seizure propagation in a brain network. The foundation invites proposals that seek to test novel, unconventional hypotheses or that pursue major methodological or technical challenges in network modeling for epilepsy. The institute is especially interested in funding innovative multi-scale approaches to brain mapping and therefore encourages proposals that can begin to correlate standard measures of macro-network activity (i.e., EEG and/or fMRI) with micro-physiological mechanisms (such as oxygen, microdialysis of extracellular fluids, local field potentials, etc). Through this initiative, the foundation seeks to support interdisciplinary approaches involving clinicians, neuroscientists, computer scientists, and mathematicians able to facilitate different perspectives and supports the development of preliminary data visualization tools for clinicians that enable them to better understand different types of seizure propagation networks that allow them to better tailor care to the individual in the future. Letter of intent due June 21, 2019. Med-RA deadline to receive draft documents: June 7. National Institute for Health Care Management (NIHCM) Foundation Investigator-Initiated Health Services Research Grants NIHCM Foundation supports innovative investigator-initiated research with high potential to inform improvements to the U.S. health care system. Projects must advance the existing knowledge base in the areas of health care financing, delivery, management and/or policy. Letter of inquiry due July 9, 2019. Med-RA deadline to receive draft documents: June 21. Exploratory Research for Technology Development (R21 - Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high-risk approaches with potential for significant impact. Projects should entail a high degree of risk or novelty, which will be offset by a correspondingly high potential impact. However, the possible impact is likely to be far off. Application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. The goal of this FOA is to support proof of concept studies for feasibility and exploratory technology development. Feasibility must not have already been developed in the literature or with preliminary data. Published data can be used to establish the current state of the art but cannot forecast or predict project outcomes. Preliminary data for any purpose might appear to forecast the likelihood of success. Therefore, no unpublished data is allowed. While unpublished data are not permitted, references and data from widely-available preprints that have a Digital Object Identifier (DOI) are acceptable. Standard dates apply. Expires May 8, 2022. Med-RA deadline to receive draft documents for June deadline: June 3. Focused Technology Research and Development (R01 ? Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) will support projects that focus solely on development of technologies with the potential to enable acquisition of basic biomedical knowledge. Projects should be justified in terms of technical innovation, and utility for future biomedical impact. The products of this research will be functioning prototype instruments, methods, synthetic approaches, biological products, etc., characterized adequately to be ready for first application to the type of biomedical research questions that provide the rationale for their development, but application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. Proof of concept for the technology must have already been demonstrated, but there should still be significant technical challenges. Applications should include preliminary data. Projects that have significant remaining risk but are supported by early feasibility studies might be appropriate for a three-year R01 application with reduced budget to better manage risk and investment. Projects that are well supported by feasibility studies and propose to develop fully functional prototypes might require higher budgets and a four-year duration (five years for Early Stage Investigators). Projects that primarily focus on optimization, hardening, or obvious extrapolations of established technology might be less competitive. Standard dates apply. Expires May 8, 2022. Med-RA deadline to receive draft documents for June deadline: May 21. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: